Systemic chemotherapy has become an integral part of primary treatment in patients with both advance and operable breast cancer. The morphological changes occurring in breast tissues have already been described, but the changes in molecular markers and the genetic variations that may occur in these tissues remain to be determine.We will study tissues obtained before and after treatment and evaluate prognostic markers as well as LOH at the p53, BRCA1 and BRCA2- locus.
| Rodriguez-Canales, J; Hanson, J C; Tangrea, M A et al. (2007) Identification of a unique epigenetic sub-microenvironment in prostate cancer. J Pathol 211:410-9 |
| Wei, M-H; Toure, O; Glenn, G M et al. (2006) Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 43:18-27 |
| Torres-Cabala, Carlos; Bibbo, Marluce; Panizo-Santos, Angel et al. (2006) Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 50:518-28 |
| Schmidt, Laura S; Nickerson, Michael L; Warren, Michelle B et al. (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 76:1023-33 |
| Pak, Ho; Gourgiotis, Loukas; Chang, Wen-I et al. (2003) Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. J Surg Oncol 82:10-8 |
